Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
126
-
Total 13F shares, excl. options
-
46.2M
-
Shares change
-
-1.78M
-
Total reported value, excl. options
-
$819M
-
Value change
-
-$247M
-
Put/Call ratio
-
0.75
-
Number of buys
-
78
-
Number of sells
-
-63
-
Price
-
$17.72
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q3 2021
169 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q3 2021.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 126 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46.2M shares
of 62.2M outstanding shares and own 74.38% of the company stock.
Largest 10 shareholders include FMR LLC (6.49M shares), Point72 Asset Management, L.P. (4.39M shares), BVF INC/IL (3.9M shares), BlackRock Inc. (3.2M shares), JOHNSON & JOHNSON (2.45M shares), FARALLON CAPITAL MANAGEMENT LLC (2.39M shares), VANGUARD GROUP INC (2.35M shares), STATE STREET CORP (2.01M shares), RTW INVESTMENTS, LP (1.75M shares), and Artal Group S.A. (1.5M shares).
This table shows the top 126 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.